menu search

TSHA / Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting Rett Syndrome. The gene therapy market is projected to grow from $15.46 billion in 2022 to $82.24 billion by 2032, highlighting a shift towards personalized medicine. TSHA-102 has received the FDA's Fast Track Designation, expediting its Phase 1/2 trial with a roadmap to treat the first pediatric patient by Q1 2024. Read More
Posted: Nov 3 2023, 19:41
Author Name: Seeking Alpha
Views: 030186

TSHA News  

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

By Seeking Alpha
November 3, 2023

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting R more_horizontal

Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?

By Zacks Investment Research
September 5, 2023

Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?

Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, more_horizontal

Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 11, 2023

Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director a more_horizontal

Taysha Gene Therapies, Inc. (TSHA) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 28, 2023

Taysha Gene Therapies, Inc. (TSHA) Q4 2022 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director more_horizontal

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

By PennyStocks
November 21, 2022

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

Biotech penny stocks to watch this week. Are they a buy now? more_horizontal

Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs

By Seeking Alpha
November 17, 2022

Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs

Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop co more_horizontal

Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript

By Seeking Alpha
November 13, 2022

Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Ch more_horizontal

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

By GlobeNewsWire
August 9, 2022

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on more_horizontal


Search within

Pages Search Results: